Lupin Bioresearch Centre Completes U.S. FDA Inspection with No Observations

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed an inspection of its Bioresearch Centre in Pune, India. Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies. The inspection closed without any observation.

"We are pleased to announce that the Lupin Bioresearch Centre has successfully undergone its seventh consecutive onsite inspection, reaffirming our commitment to patient safety and our superior quality and compliance standards," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 656.35 as compared to the previous close of Rs. 657.20. The total number of shares traded during the day was 10266 in over 719 trades.

The stock hit an intraday high of Rs. 658.25 and intraday low of 649.55. The net turnover during the day was Rs. 6717417.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA Inspection BioresearchCentre Pune India